Cardiac safety evaluation on drugs using the TRIaD assay in the rabbit cardiac monophasic action potential (토끼 심장에서 단상활동전위의 TRIaD 분석을 이용한 약물에 대한 심장 안전성 평가)

Jong-Tak Han (한종탁); Dae-Hwan Nam (남대환); Sun-Hyun Park (박순현); Ki-Sik Kim (김기석)

doi:10.23032/jaae.2017.11.1.001

Cardiac safety evaluation on drugs using the TRIaD assay in the rabbit cardiac monophasic action potential

Journal of Alternatives to Animal Experiments
Abbr : J Altern Anim Exp
2017, 11(1), pp.1-9
DOI : 10.23032/jaae.2017.11.1.001
Publisher : Korean Society for Alternatives to Animal Experiments
Research Area : Medicine and Pharmacy > Veterinary > Basic Veterinary Medicine > Laboratory Animal Medicine
Received : December 18, 2017
Accepted : December 21, 2017
Published : December 29, 2017

Jong-Tak Han ¹, Dae-Hwan Nam ¹, Sun-Hyun Park ², Ki-Sik Kim ¹

¹한국화학연구원 부설 안전성평가연구소 예측모델연구센터
²한국화학연구원 부설 안정성평가연구소 예측모델연구센터

ABSTRACT

Drug-induced torsades de pointes (TdP) have been linked to a sudden cardiac death. Prolongation of the action potential duration (APD) and the QT interval (PQT), in nonclinical assays, have been investigated before drug development. However, TdP can often occur without any appreciable QT prolongation, and drug development companies and researchers may ask better accurate models or methods. We wish to verify whether it is effective to determine the cardiac toxicity as a result of the measurement using the TRIaD assay in the rabbit cardiac monophasic action potential. ‘TRIaD’ means Trianguation, Reverse use dependence, Instability and Dispersion. In this study, to confirm this assay, control, negative control and positive control were classified based on the degree of cardiotoxicity. Control group was perfused by only normal Tyrode’s solution. Diltiazem and Amoxicillin were used as negative controls. Terfenadine, Quinidine, Amiodarone, and Nifedipine were used as positive controls. Based on these, proarrhythmic scores were calculated as follow: instability 20 points, triangulation 10 points, and RUD 5 points. Both in control and negative groups, proarrhythmic score did not exceed the 25 points, but exceeded in all positive groups. These data propose that this is robust and reliable assay that can add value to drug-induced prolongation/TdP risk assessment. Additionally, this assay provides detailed information on the overall profile of drug-induced electrophysiological effects. Therefore, TRIaD assay can be a valuable to establish for the cardiovascular risk assessment of drugs.

KEYWORDS

Proarrhythmic, MAP, TRIaD assay, rabbit cardiac monophasic action potential

Citation status

* References for papers published after 2023 are currently being built.

[journal] Anderson, J. L. / 2004 / Antibiotic Trials for Coronary Heart Disease / Tex Heart Inst J 31(1) : 33~38

[journal] Antzelevitch, C. / 2002 / Cellular mechanisms underlying the long QT syndrome / Curr Opin Cardiol 17(1) : 43~51

[journal] Baykal, B. / 2015 / Comparison of effects of nifedipine and ritodrine on maternal and fetal blood flow patterns in preterm labor / J Turk Ger Gynecol Assoc 16(2) : 80~85

[journal] Boden, W. E. / 2001 / Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem / Clin Cardiol 24(1) : 73~79

[journal] Dumotier, B. M. / 2008 / Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: A database review and analysis / Pharmacology & Therapeutics 119(2) : 152~159

[journal] Fang, L. S. T. / 1978 / Efficacy of Single-Dose and Conventional Amoxicillin Therapy in Urinary Tract Infection Localized by the Antibody-Coated Bacteria Technic / New England Journal of Medicine 298(8) : 413~416

[journal] Frishman, W. H. / 1985 / Comparison of diltiazem and nifedipine for both angina pectoris and systemic hypertension / The American Journal of Cardiology 56(16) : H41~H46

[journal] Grace, A. A. / 1998 / Quinidine / New England Journal of Medicine 338(1) : 35~45

[journal] Herrington, D. M. / 1986 / ifedipine overdose / Am J Med 81(2) : 344~346

[journal] Hii, J. T. / 1992 / Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone / Circulation 86(5) : 1376~1382

[journal] Hondeghem, L. M. / 2005 / TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability) / Novartis Found Symp 266 : 235~244

[journal] Horowitz, L. N. / 1987 / Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia--a status report, 1987 / Am J Cardiol 59(11) : 54e~56e

[other] ICH, S. A. / 2000 / Safety pharmacology studies for human pharmaceuticals

[journal] ICH, S. B. / 2005 / The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals / ICH S7B 16(2) : 79~81

[journal] Kloner, R. A. / 1995 / Nifedipine in Ischemic Heart Disease / Circulation 92(5) : 1074~1078

[journal] Lawrence, C. L. / 2006 / A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes / Br J Pharmacol 149(7) : 845~860

[journal] Lester, R. M. / 2016 / Early drug development: assessment of proarrhythmic risk and cardiovascular safety / Expert Rev Clin Pharmacol 9(12) : 1611~1618

[journal] Li, M. / 2017 / Drug-Induced QT Prolongation And Torsades de Pointes / P t 42(7) : 473~477

[journal] Milberg, P. / 2002 / Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes / J Pharmacol Exp Ther 303(1) : 218~225

[journal] Nachimuthu, S. / 2012 / Drug-induced QT interval prolongation: mechanisms and clinical management / Ther Adv Drug Saf 3(5) : 241~253

[journal] Nawrath, H. / 1984 / Antimuscarinic action of quinidine on the heart? A study in myocardial preparations from cat hearts / Br J Pharmacol 81(1) : 103~111

[journal] Olasińska-Wiśniewska, A. / 2014 / Cardiovascular safety of antihistamines / Postepy Dermatol Alergol 31(3) : 182~186

[journal] Personett, H. A. / 2014 / Intravenous metoprolol versus diltiazem for rate control in noncardiac, nonthoracic postoperative atrial fibrillation / Ann Pharmacother 48(3) : 314~319

[journal] Roy, D. / 2000 / Amiodarone to Prevent Recurrence of Atrial Fibrillation / New England Journal of Medicine 342(13) : 913~920

[journal] Shantsila, E. / 2007 / Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias / EP Europace 9(suppl_4) : iv37~iv44

[journal] Wiśniowska, B. / 2016 / Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials / BMC Pharmacol Toxicol 17

[journal] Woosley, R. L. / 1993 / Mechanism of the cardiotoxic actions of terfenadine / Jama 269(12) : 1532~1536

[journal] Wroblewski, H. A. / 2012 / High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis / Antimicrob Agents Chemother 56(8) : 4495~4499

KJCKorea
Journal Central

Journal of Alternatives to Animal Experiments 2023 KCI Impact Factor : 0.07

Cardiac safety evaluation on drugs using the TRIaD assay in the rabbit cardiac monophasic action potential

ABSTRACT

KEYWORDS

Citation status

* References for papers published after 2023 are currently being built.

Journal of Alternatives to Animal Experiments 2023 KCI Impact Factor : 0.07

Cardiac safety evaluation on drugs using the TRIaD assay in the rabbit cardiac monophasic action potential

ABSTRACT

KEYWORDS

Statistics

Tools

Issue List

Citation status

KCI Citation Counts (0)

REFERENCES (28) * References for papers published after 2023 are currently being built.

Search PDF

Citation

* References for papers published after 2023 are currently being built.